THE EVOLUTION AND FUTURE OF CRISPR THERAPEUTICS

Print

TAG: GS 3: SCIENCE AND TECHNOLOGY

THE CONTEXT: The recent approvals by regulatory agencies in the UK and the US for CRISPR-based therapies targeting sickle-cell disease and β-thalassemia mark a transformative era in medicine.

EXPLANATION:

• These inherited blood disorders affect millions globally, and the approvals signify a shift towards addressing their molecular basis rather than just symptom management.

THE EVOLUTION OF CRISPR TECHNOLOGY

• Origins of CRISPR
  • CRISPR, an acronym for Clustered Regularly Interspaced Short Palindromic Repeats, originated from the discovery of DNA elements in 1993 by Spanish researchers.
  • These elements were found in archaea and later in bacterial genomes.
  • Initially thought to be a part of the bacterial immune system against viruses, it was revealed that CRISPR, combined with CRISPR-associated proteins (Cas), functioned as an antiviral defense mechanism.
• Milestone Discoveries
  • The groundbreaking work of Emmanuelle Charpentier, Jennifer Doudna, and Virginijus Siksnys led to key discoveries.
  • In 2010, it was demonstrated that CRISPR, specifically with Cas9 proteins, could cut DNA at precise points.
  • The identification of RNA molecules guiding Cas9 to specific genomic positions further revolutionized its potential.
  • This work culminated in the development of a programmable ‘molecular scissor’ capable of editing DNA accurately.
• CRISPR-Cas9 Advancements
  • Subsequent research by Feng Zhang and George Church showcased CRISPR-Cas9’s ability to edit the genomes of eukaryotic organisms.
  • This innovation expanded its applications, ranging from genetic therapies to agricultural advancements.

CRISPR IN MEDICINE: CURRENT ACHIEVEMENTS AND FUTURE PROSPECTS

• First-Generation Technologies
  • The approved CRISPR-based therapeutics represent first-generation technologies.
  • Though groundbreaking, they are continuously evolving to become more efficient and effective.
  • Novel approaches like base editing and prime editing hold immense promise for precise genome editing at the nucleotide level, addressing diseases like familial hypercholesterolemia.
• Emerging Techniques and Challenges
  • Techniques like base editing and prime editing are showing potential, yet safety and accuracy issues persist.
  • Off-target events, where CRISPR systems inaccurately edit unintended parts of the genome, pose risks.
  • Balancing short-term benefits with long-term risks remains critical, especially as these therapies are still in early developmental stages.

THE FUTURE LANDSCAPE AND CONSIDERATIONS

• Potential and Caution
  • While celebrating the transformative potential of CRISPR-based therapies like Casgevy, it’s essential to acknowledge potential risks.
  • Continued scrutiny and surveillance are imperative to identify and address unforeseen side effects.
  • The enormous promise of these technologies must be cautiously balanced with potential risks to ensure patient safety and ethical considerations.
• Moving Forward
  • CRISPR technology has opened doors to a future where the correction of genetic anomalies is a reality.
  • The ongoing advancements in CRISPR-based therapies signify a promising era in medicine, holding immense potential to alleviate the suffering of millions affected by genetic diseases.

CONCLUSION

• The approval of CRISPR-based therapies represents a significant leap in medical science, offering hope to patients with genetic disorders.
• While these treatments mark a milestone, continuous research, vigilance, and technological advancements are crucial to maximize benefits while minimizing risks associated with genome editing technologies.

SOURCE: https://www.thehindu.com/sci-tech/science/crispr-casgevy-sickle-cell-disease-genetic-therapeutics-explained/article67641478.ece